<DOC>
	<DOCNO>NCT01098266</DOCNO>
	<brief_summary>The main objective trial document efficacy NGR-hTNF administer low dose weekly advance Malignant Pleural Mesothelioma patient previously treat pemetrexed-based chemotherapy regimen .</brief_summary>
	<brief_title>NGR015 : Study Second Line Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed</brief_title>
	<detailed_description>Currently , regulatory-approved widely accept treatment option patient fail standard pemetrexed-based chemotherapy regimen . For reason , best supportive care ( BSC ) alone might consider standard reference randomize phase III trial setting . However , single-agent chemotherapeutic agent ( doxorubicin , gemcitabine , vinorelbine ) well-documented safety profile antitumor activity also use clinical practice . Therefore , best investigator 's choice ( BIC ) either best supportive care alone combine select single-agent chemotherapy ( include doxorubicin , gemcitabine , vinorelbine ) might consider acceptable reference arm well set . The current phase III study aim show superior efficacy term overall survival duration NGR-hTNF 0.8 µg/mq weekly plus BIC versus placebo plus BIC advance MPM patient progress standard pemetrexed-based chemotherapy .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<criteria>Age ≥ 18 year Histologically cytological confirm malignant pleural mesothelioma follow subtype : epithelial , sarcomatoid , mixed , unknown Prior treatment one systemic pemetrexedbased chemotherapy regimen administer advanced metastatic disease . Prior use biological agent combination pemetrexedbased regimen prior administration intrapleural cytotoxic agent allow . Patients previously receive anthracyclines receive doxorubicin ECOG Performance Status 0 2 Life expectancy ≥ 12 week Adequate baseline bone marrow , hepatic renal function , define follow : 1 . Neutrophils ≥ 1.5 x 109/L ; platelet ≥ 100 x 109/L ; hemoglobin ≥ 9 g/dL 2 . Bilirubin ≤ 1.5 x ULN 3 . AST and/or ALT ≤ 2.5 x ULN absence liver metastasis ≤ 5 x ULN presence liver metastasis 4 . Serum creatinine &lt; 1.5 x ULN Measurable nonmeasurable disease accord MPMmodified RECIST criterion Patients may prior therapy provide follow condition meet : 1 . Surgery : washout period 14 day 2 . Systemic radiation antitumor therapy : washout period 28 day Patients must give write informed consent participate study Patients must receive investigational agent study Patients myocardial infarction within last six month , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication Uncontrolled hypertension QTc interval ( congenital acquire ) &gt; 450 ms History evidence upon physical examination CNS disease unless adequately treat ( e.g. , primary brain tumor , brain metastasis , seizure control standard medical therapy , history stroke ) Patients active uncontrolled systemic disease/infections serious illness medical condition , incompatible protocol Known hypersensitivity/allergic reaction human albumin preparation excipients Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>MPM</keyword>
	<keyword>NGR-hTNF</keyword>
	<keyword>NGR-hTNF plus BIC</keyword>
	<keyword>Randomized double-blind phase III study</keyword>
</DOC>